Novartis Adds Osteoporosis Claim For Reclast, Plans Prevention Filing By Year End
Executive Summary
Novartis plans to file an osteoporosis prevention claim for Reclast (zoledronic acid) by the end of 2007, the company told "The Pink Sheet" after the bisphosphonate's Aug. 17 approval for osteoporosis treatment. The Swiss firm will seek an indication for prevention of clinical fractures after hip fracture in both men and women
You may also be interested in...
The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent
Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond
The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent
Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond
Novartis’ Reclast Gains Paget’s Approval, But Still Waiting On Osteoporosis
Novartis' Paget's disease treatment Reclast (zoledronic acid) will launch with an apparent pricing advantage over the current standard of care, Proctor & Gamble's Actonel (risedronate)
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: